1. Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
   Zohaib Rana et al, 2020, Biomedicines CrossRef
2. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells
   Laurence Booth et al, 2021, Frontiers in Oncology CrossRef
3. Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
   Julia Krushkal et al, 2024, Epigenetics CrossRef
4. Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic Cancer
   Chin-King Looi et al, 2022, Cancers CrossRef
5. Neratinib kills B‐RAF V600E melanoma via ROS‐dependent autophagosome formation and death receptor signaling
   Paul Dent et al, 2022, Pigment Cell & Melanoma Research CrossRef
6. Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression
   Ananda Ayyappan Jaguva Vasudevan et al, 2022, Scientific Data CrossRef
7. Histone Deacetylases and Their Potential as Targets to Enhance Tumour Radiosensitisation
   Jennifer Antrobus et al, 2022, Radiation CrossRef
8. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
   Martina Korfei et al, 2022, Cells CrossRef
9. Insights Into the Function and Clinical Application of HDAC5 in Cancer Management
   Jun Yang et al, 2021, Frontiers in Oncology CrossRef
10. Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
    Dimitrios Goutas et al, 2021, Diagnostics CrossRef
11. HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway
    Lei Yu et al, 2023, Open Medicine CrossRef
12. Stenotrophomonas maltophilia promotes lung adenocarcinoma progression by upregulating histone deacetylase 5
    Jiyu Shen et al, 2023, Frontiers in Microbiology CrossRef